We scan new podcasts and send you the top 5 insights daily.
Tom said no pre-surgery ctDNA-positive patient achieved pCR in EV304 or Niagara. Among ctDNA-negative patients, pCR was 75% with EV+Pembro but roughly 50-50 with chemotherapy. That makes bladder-sparing risky while ctDNA remains positive; the test is not a green light for less local therapy.
The prognostic value of a positive ctDNA test in urothelial cancer intensifies throughout the treatment journey. Failure to clear ctDNA after neoadjuvant therapy and then surgery is associated with a dramatically increasing hazard ratio for death, signaling profound treatment failure.
Tom argued pCR reflects local drug activity in the bladder and matters less when everyone undergoes cystectomy, while ctDNA reflects clearance of micrometastases. Their imperfect alignment is expected because the tests measure different processes and have different sensitivity and specificity. Neither is a complete proxy for the other.
Tom noted post-surgery ctDNA positivity fell to 5% on EV+Pembro versus 15% on chemotherapy, and the chemo arm also declined. He suspects surgery accounts for only part of the drop, with delayed immune clearance from EV+Pembro contributing; the durability of response evolves over months. So the surgical effect is not the whole story.
Circulating tumor DNA (ctDNA) provides more actionable risk stratification than pathologic stage in resected upper tract disease. Patients who test ctDNA negative exhibit a low 20% to 30% risk of recurrence, making active surveillance reasonable to avoid toxic, marginally effective adjuvant therapies. Conversely, ctDNA positivity behaves like occult metastatic disease with recurrence rates approaching 95%, prompting clinicians to bypass adjuvant platinum for full-dose enfortumab vedotin plus pembrolizumab.
While positive ctDNA is a clear indicator of disease, a negative result must be interpreted with caution. Clinical trial data shows even ctDNA-negative patients can benefit from adjuvant therapy, suggesting undetectable levels do not guarantee the absence of micrometastatic disease that still requires treatment to prevent recurrence.
John Chatzko reported that 82% of baseline ctDNA-positive patients cleared ctDNA before surgery on EV+Pembro versus 67% on gem/cis. Among those clearers, two-year EFS was 81% versus 63%, suggesting EV+Pembro drives a deeper biologic response. That gap implies the quality, not just frequency, of clearance differs by regimen.
Experts find a positive circulating tumor DNA (ctDNA) test more useful for informing a decision to start adjuvant therapy. A negative result is considered less helpful and doesn't provide the same level of reassurance or definitively rule out treatment, as the pivotal clinical trial was designed to address the ctDNA-positive scenario.
While circulating tumor DNA (ctDNA) is a powerful prognostic marker, it is not yet part of the formal "clinical complete response" definition for bladder-sparing trials. Experts lack data on its ability to predict the superficial, non-muscle invasive relapses common in this setting.
In muscle-invasive bladder cancer, patients whose cell-free DNA remains positive after surgery almost uniformly experience disease relapse. This makes ctDNA a powerful prognostic tool, akin to PSA in prostate cancer, for identifying patients at the highest risk.
Tom noted 24-month EFS was 94% in EV+Pembro patients who were ctDNA-negative at baseline and stayed negative, but John Chatzko cautioned that about a quarter of pre-surgery ctDNA-negative EV+Pembro patients still lacked pCR. They favored randomized de-escalation trials over routine treatment reduction; the high survival is real, but causal attribution is not.